FLORHAM PARK, N.J., Jan. 13, 2021 /PRNewswire/ — Celularity Inc., a clinical-stage cell therapeutics company focused on the...
Your browser does not support the audio element. Thank you for joining the conference call...
Celularity has entered into a definitive merger agreement with GX Acquisition Corp. (Nasdaq: “GXGX”); upon...
FLORHAM PARK, N.J., Dec. 1, 2020 /PRNewswire/ — Celularity announced today that the independent Data Monitoring Committee (DMC) completed...
Celularity announced today that the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial. The patient was treated at UC Irvine in California, the first CA site to open for patient enrollment with support from a COVID-19 Project grant awarded to Celularity by the California Institute for Regenerative Medicine (CIRM). Participating trial sites include Hackensack University Medical Center and Atlantic Health in New Jersey, MultiCare Health System in Washington State, Banner University Medical Center Phoenix in Arizona, the University of Arkansas in Arkansas, and UC Davis in California. The Principal Investigator is Corey Casper, M.D., MPH, of the Infectious Disease Research Institute (IDRI) ClinicalTrials.gov Identifier: NCT04365101.
Celularity, Inc. (”Celularity” or “the Company”) today announced that it has sold its UltraMIST® Ultrasound...
University of California Irvine is the first California site participating in Celularity’s CYNK-001-COVID-19 clinical trial...
The expanded strategic collaboration includes the use of Celularity's proprietary CYNK-001 for treatment of SARS-CoV-2 virus, which causes COVID-19 and Acute Respiratory Distress Syndrome
CYNK-001, the company's allogeneic, off-the-shelf, cryopreserved Natural Killer cell therapy to be used in Phase I/II study
Dr. Robert Hariri, CEO and founder of Celularity, discusses how the company is exploring a...
